Dementia and Alzheimer Disease

The chief medical officer at SanBio discussed how the investigational agent SB623 can fill the void of disease-modifying therapies for TBI.

Neurology News Network for the week ending January 23, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 22, 2021.

The asymmetry of mediotemporal atrophy and a lesser impact of APOE4 and TDP-43 on the integrity of memory circuitry may have constituted preservation in primary progressive aphasia.

The associate professor at Hokkaido University and investigator of STEMTRA also discussed other efforts in stroke, Alzheimer disease, and Parkinson disease.

Hippocampal-sparing and limbic-predominant atrophy were also associated with incident dementia, with faster cognitive decline in the limbic predominant atrophy group.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine detailed his study on the correlations between sleep and cognitive decline in middle-aged Hispanics.

New technology enables the collection and analysis of speech behaviors, but this requires an extensive database, which the ADDF seeks to help develop.

New NIH-funded study tests home-based intervention in high-risk group.

Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%, according to Abbott, the test’s developer.

Here's what is coming soon to NeurologyLive.

Maha Radhakrishnan, MD, the Group SVP and chief medical officer at Biogen, discussed the collaborative study between Biogen and Apple that’s expected to kick off later this year.

Neurology News Network for the week ending January 16, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.

The findings suggest and confirm previous studies that suggested plasma p-tau181 may be used as a measure to monitor Alzheimer disease progression in clinical practice and treatment trials.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

Researchers found amyloid-β positron emission tomography imaging and dopamine transporter imaging to be useful in characterizing phenotypes of the neurodegenerative conditions.

There was no statistically significant difference between treatment-related adverse events in the SB623 stem cell and control groups.

The follow-up TRAILBLAZER-EXT and broader population TRAILBLAZER-ALZ 2 studies are currently ongoing.

Here's what is coming soon to NeurologyLive.

Health care professionals and a caregiver discuss the overall burden of hallucinations and delusions associated with dementia-related psychosis, explore unmet needs in diagnosis and management of these symptoms, and discuss the need for increased dialogue between clinicians and caregivers.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

UFC will provide $1 million contribution to fund research for a 5-year study that examines the effect of head impacts on long-term brain health.

Women with HDP were found to perform worse on cognitive tests 15 years after delivery than their counterparts.

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.